Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.71 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.71 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.71 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | DGKA | P23743 | 1/20 | 0.56 |
| ▸ | SELP | P16109 | 1/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.56 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.55 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1835410 | 1.00 | PRKCA (0.71) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL8845386 | 0.96 | PRKCA (0.67) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL8356370 | 0.92 | ALDH1A1 (0.77) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL1528029 | 0.90 | PRKCA (0.86) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL25386239 | 0.90 | PRKCA (0.86) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL23225841 | 0.90 | PRKCA (0.86) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL21641598 | 0.90 | PRKCA (0.86) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL21443903 | 0.90 | PRKCA (0.86) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL21439775 | 0.90 | PRKCA (0.86) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL638987 | 0.90 | PRKCA (0.86) | PRKCAPRKCEPRKCQPRKCDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322143-B1 | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes | PACIRA PHARMACEUTICALS INC (US) | 2017-01-11 | — | — | EP | disclosed |
| EP-0971699-B1 | METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES | PACIRA PHARMACEUTICALS INC (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2322143-A1 | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes | Pacira Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-5962016-A | A FAMILY OF MVL FORMULATIONS CONTAINING DIFFERENT SLOW:FAST RELEASE NEUTRAL LIPID MOLAR RATIOS DISPLAY DIFFERENT RELEASE RATES DEPENDING UPON THE MOLAR RATIO OF THE FAST RELEASE NEUTRAL LIPID TO THE SLOW RELEASE NEUTRAL LIPID IN EACH | DEPOTECH CORPORATION (US) | 1999-10-05 | — | — | US | disclosed |
| US-5891467-A | ENCAPSULATION AND RELEASE OF ACTIVE COMPOUNDS | DEPOTECH CORPORATION (US) | 1999-04-06 | — | — | US | disclosed |